SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in diabetic macular edema and wet age-related macular degeneration.
Javaheri reported an average treatment interval of 70 days in treatment-naive patients with DME or wet AMD.
Additionally, patients with initial treatment intervals of less than 6 weeks experienced treatment extensions of 2 to 3 weeks after switching to Eylea HD (aflibercept injection 8 mg, Regeneron) from other anti-VEGF agents. Patients with initial treatment intervals that were longer than